Stock analysts at StockNews.com assumed coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) in a research report issued on Saturday. The firm set a “hold” rating on the ...

Elite Pharmaceuticals, with a market capitalization of $531 million, reported a decline in third-quarter revenue for 2024, falling 8% from the previous year. Despite a strong nine-month performance, ...

After back-to-back years of 20%-plus gains in 2023 and 2024, the S&P 500 is off to another strong start to 2025. However, the S&P 500's forward earnings multiple of 22 (as of Feb. 7) was also ...

Q4 2024 Earnings Call Transcript February 13, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported ...

Choreo LLC trimmed its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 5.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange ...

In this process, royalty recipients often face the issue where multiple small future royalty streams cannot fulfill ongoing large lump-sum R&D funding needs. The mismatch is where Royalty Pharma ...

The S&P 500 advanced 1.0% on Thursday, Feb. 13, as an executive order deferred the possible implementation of reciprocal ...

West Pharmaceutical Services Inc.'s stock tumbled 33% Thursday, to lead S&P 500 decliners, after the manufacturer of injectable-pharmaceutical packaging and delivery systems offered guidance for 2025 ...

Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...